Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism
J M MeijerHendrika Bootsma

Abstract

To study the efficacy and safety of B cell depletion with rituximab, a chimeric murine/human anti-CD20 monoclonal antibody, in patients with primary Sjögren's syndrome (SS) in a double-blind, randomized, placebo-controlled trial. Patients with active primary SS, as determined by the revised American-European Consensus Group criteria, and a rate of stimulated whole saliva secretion of > or =0.15 ml/minute were treated with either rituximab (1,000 mg) or placebo infusions on days 1 and 15. Patients were assigned randomly to a treatment group in a ratio of 2:1 (rituximab:placebo). Followup was conducted at 5, 12, 24, 36, and 48 weeks. The primary end point was the stimulated whole saliva flow rate, while secondary end points included functional, laboratory, and subjective variables. Thirty patients with primary SS (29 female) were randomly allocated to a treatment group. The mean +/- SD age of the patients receiving rituximab was 43 +/- 11 years and the disease duration was 63 +/- 50 months, while patients in the placebo group were age 43 +/- 17 years and had a disease duration of 67 +/- 63 months. In the rituximab group, significant improvements, in terms of the mean change from baseline compared with that in the placebo group, w...Continue Reading

Associated Clinical Trials

References

Sep 1, 1973·Archives of Oral Biology·D B FergusonA J Potts
Feb 1, 1972·The Journal of Physiology·C Dawes
Apr 1, 1995·Journal of Psychosomatic Research·E M SmetsJ C De Haes
Nov 16, 2001·Annals of the Rheumatic Diseases·W W KalkA V Nieuw Amerongen
Jan 18, 2002·Annals of the Rheumatic Diseases·W W I KalkC G M Kallenberg
May 15, 2002·Annals of the Rheumatic Diseases·C VitaliUNKNOWN European Study Group on Classification Criteria for Sjögren's Syndrome
Nov 20, 2004·Annals of the Rheumatic Diseases·J-E GottenbergUNKNOWN Club Rheumatismes et Inflammation (CRI)
Oct 6, 2005·European Journal of Oral Sciences·Fred R BurlageArjan Vissink
May 27, 2006·Annals of the Rheumatic Diseases·J PijpeA Vissink
Mar 3, 2007·Arthritis and Rheumatism·Valérie Devauchelle-PensecAlain Saraux
Nov 10, 2007·Clinical Reviews in Allergy & Immunology·Jiska M MeijerCees G M Kallenberg
Mar 14, 2008·Seminars in Arthritis and Rheumatism·Roy M Fleischmann
Nov 13, 2008·International Immunopharmacology·Hakan M GürcanA Razzaque Ahmed

❮ Previous
Next ❯

Citations

Jan 27, 2011·Zeitschrift für Rheumatologie·S Briem, H-M Lorenz
Dec 12, 2012·Zeitschrift für Rheumatologie·T Witte
Nov 7, 2013·Zeitschrift für Rheumatologie·I Kötter, J C Henes
Oct 12, 2012·Current Allergy and Asthma Reports·Jennifer L RogersTeresa K Tarrant
Jan 24, 2013·Drugs & Aging·Rada V MoermanArjan Vissink
Sep 5, 2012·Nature Reviews. Rheumatology·Kenneth L RockJiann-Jyh Lai
May 3, 2012·Nature Reviews. Rheumatology·Manuel Ramos-CasalsAthanasios G Tzioufas
Jul 17, 2013·Nature Reviews. Rheumatology·Gaëtane Nocturne, Xavier Mariette
Jul 31, 2010·Current Opinion in Rheumatology·Xavier Mariette, Jacques-Eric Gottenberg
Mar 28, 2012·Current Opinion in Rheumatology·Arjan VissinkCees G M Kallenberg
Aug 9, 2012·Current Opinion in Rheumatology·Andreea Coca, Iñaki Sanz
Jan 10, 2012·International Journal of Rheumatology·Courtney L Kraus, Susan M Culican
Jul 5, 2012·BMC Musculoskeletal Disorders·Sven-Ulrik GorrSara A Michie
Apr 6, 2013·BMC Medicine·Angela TincaniYehuda Shoenfeld
Mar 5, 2011·Arthritis Research & Therapy·Cees G M KallenbergHendrika Bootsma
Jul 13, 2011·Arthritis Research & Therapy·Cándido Díaz-LagaresUNKNOWN BIOGEAS Study Group
Oct 15, 2011·Arthritis Research & Therapy·Karstein HaldorsenJohan Gorgas Brun
Nov 26, 2010·Immunotherapy·Rebecca Manno, Francesco Boin
Aug 30, 2013·Medicina oral, patología oral y cirugía bucal·Antonio Bascones-MartinezJukka H Meurman
Feb 21, 2014·Zeitschrift für Rheumatologie·T Witte
Jun 4, 2013·Immunotherapy·Divi CornecJacques-Olivier Pers
Oct 29, 2013·Annual Review of Medicine·Mikkel Faurschou, David R W Jayne
Apr 20, 2012·Immunotherapy·Christopher D RudulierPeter A Bretscher
Dec 7, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·N RoescherJacques-Eric Gottenberg
Mar 30, 2013·Autoimmunity Reviews·Sonia Berrih-AkninRobert P Lisak
Jan 22, 2014·Rheumatology·Georg Franz LehnerManfred Herold
Jan 26, 2013·Expert Opinion on Pharmacotherapy·Pilar Brito-ZerónManuel Ramos-Casals
Feb 22, 2013·Expert Opinion on Pharmacotherapy·Robert M BeardsleyPhoebe Lin
Mar 22, 2014·Expert Review of Clinical Immunology·Alia FazaaJacques-Eric Gottenberg
Feb 26, 2014·Expert Review of Clinical Immunology·Frans G M KroeseHendrika Bootsma
Feb 5, 2014·Expert Review of Clinical Immunology·Francesco CicciaGiovanni Triolo
Dec 7, 2013·Expert Review of Clinical Immunology·Samuel Morris-RosenfeldColeen A McNamara
Jan 24, 2014·Expert Review of Clinical Immunology·Maarten R HillenJoel A Van Roon
Aug 9, 2011·Expert Opinion on Biological Therapy·Petra M MeinersHendrika Bootsma
Apr 5, 2011·Expert Opinion on Biological Therapy·Wan-Fai Ng, Simon J Bowman
Oct 30, 2015·Rheumatology·Clare OniUNKNOWN UK Primary Sjögren’s Syndrome Registry
Jan 26, 2016·Expert Opinion on Drug Safety·Jolien F van NimwegenArjan Vissink

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.